Breaking News Instant updates and real-time market news.

RHHBY

Roche

$0.00

(0.00%)

13:02
10/21/18
10/21
13:02
10/21/18
13:02

Genentech's Tecentriq, Abraxane combo demonstrates positive Phase III results

Genentech, a member of the Roche, announced positive results from the Phase III IMpassion130 study of Tecentriq plus chemotherapy - Abraxane - for the initial treatment of unresectable locally advanced or metastatic triple-negative breast cancer. The Tecentriq and chemotherapy combination significantly reduced the risk of disease worsening or death compared with chemotherapy alone in all randomized patients and the PD-L1-positive population, a subgroup determined by PD-L1 biomarker testing. At this interim analysis, statistical significance was not met for overall survival in the ITT population, but showed a clinically meaningful 9.5-month OS improvement in the PD-L1-positive population. Due to the hierarchical statistical design, results in the PD-L1-positive population were not formally tested. Follow-up will continue until the next planned analysis. Safety in the Tecentriq plus nab-paclitaxel arm appeared consistent with the known safety profiles of the individual medicines, and no new safety signals were identified with the combination.

  • 21

    Oct

  • 07

    Nov

  • 24

    Dec

RHHBY Roche
$0.00

(0.00%)

10/03/18
BARD
10/03/18
NO CHANGE
Target $348
BARD
Neutral
Risdiplam data incrementally negative for Biogen, says Baird
Biogen analyst Brian Skorney views this morning's risdiplam data for use in treating spinal muscular atrophy patients as incrementally negative for Biogen (BIIB). The data from PTC Therapeutics (PTCT) and PTC Therapeutics (RHHBY) are compelling so far, and suggest that risdiplam could impact the market share of Biogen's Spinraza, if it comes to market, Skorney tells investors in a research note. He highlights risdiplam's convenience as an oral small molecule and says the Phase II data "continues to impress." The analyst keeps a Neutral rating on Biogen with a $348 price target. The stock in afternoon trading is up $6.90, or 2%, to $352.31.
10/08/18
SBSH
10/08/18
NO CHANGE
Target $470
SBSH
Buy
Biogen price target lowered to $470 from $483 at Citi
Citi analyst Robyn Karnauskas lowered her price target for Biogen (BIIB) to $470 after reducing her assumptions for Rituxan/Gazyva co-promotion profits to reflect greater erosion from biosimilar versions of Rituxan that are expected to launch late 2018/early 2019. The analyst points out that consensus estimates are not modeling significant co-promotion profit erosion from Rituxan biosimilars. However, the Roche (RHHBY) consensus for Rituxan has steep declines in Rituxan sales, Karnauskas tells investors in a research note. The analyst now models a 45% total decline in Rituxan/Gazyva U.S. sales over 2018-2023. She keeps a Buy rating on Biogen.
10/15/18
RBCM
10/15/18
NO CHANGE
RBCM
Sector Perform
Roche breast cancer data could pressure Puma shares, says RBC Capital
RBC Capital analyst Kennen MacKay thinks the data presented this morning by Roche's (RHHBY) Genentech could pressure shares of Puma Biotechnology (PBYI) today. Genentech announced the Phase III Katherine study met its primary endpoint, showing Kadcyla as a single agent reduced the risk of disease recurrence or death compared to Herceptin as an adjuvant treatment in people with HER2-positive early breast cancer who have residual disease present following neoadjuvant treatment. Kadcyla's ultimate entry into the HER2-positive adjuvant setting could complicate the positioning of Puma's Nerlynx, MacKay tells investors in a research note. He keeps a Sector Perform rating on shares of Puma, which are down 4%, or $1.55, to $41.14 in morning trading.
10/16/18
WELS
10/16/18
NO CHANGE
WELS
Drug price in ads not impactful, may cause confusion, says Wells Fargo
Wells Fargo analyst David Maris acknowledges that the U.S. Department of Health and Human Services' proposal to include drug prices in advertisements has a "noble goal" of making drugs more affordable and keeping patients well informed. However, given how different list prices are relative to out of pocket costs, "one must ask if this is increasing transparency or likely going to lead to more confusion," he contends. The analyst also believes that the unintended consequence could be worse care, while noting that the drug price information will likely fall into the category of the side effect information in drug ads currently, tuned out by many and will have no material impact. While he supports the idea of increased transparency, Maris wonders whether the potential benefit is not outweighed by the potential negative for the most vulnerable. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).

TODAY'S FREE FLY STORIES

XOM

Exxon Mobil

$69.11

0.37 (0.54%)

17:58
10/22/19
10/22
17:58
10/22/19
17:58
Periodicals
Exxon lawyer slams NY climate suit as trial opens, Bloomberg says »

Exxon Mobil attorney…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

TER

Teradyne

$59.24

-0.83 (-1.38%)

17:57
10/22/19
10/22
17:57
10/22/19
17:57
Hot Stocks
Teradyne jumps 6% after quarterly results, guidance based on 5G demand »

Shares of semiconductor…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 31

    Oct

TER

Teradyne

$59.24

-0.83 (-1.38%)

17:53
10/22/19
10/22
17:53
10/22/19
17:53
Earnings
Teradyne sees Q4 EPS 73c-84c, consensus 61c »

Sees Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 31

    Oct

LEVI

Levi Strauss

$17.59

0.58 (3.41%)

17:52
10/22/19
10/22
17:52
10/22/19
17:52
Hot Stocks
Levi Strauss EVP Love sells 204K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BK

BNY Mellon

$46.15

0.48 (1.05%)

, WFC

Wells Fargo

$50.63

0.18 (0.36%)

17:51
10/22/19
10/22
17:51
10/22/19
17:51
Periodicals
BNY Mellon vice chairman leaves lender, WSJ says »

Bill Daley, former White…

BK

BNY Mellon

$46.15

0.48 (1.05%)

WFC

Wells Fargo

$50.63

0.18 (0.36%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Oct

  • 29

    Oct

  • 12

    Nov

  • 14

    Jan

FMBI

First Midwest

$20.13

0.11 (0.55%)

17:42
10/22/19
10/22
17:42
10/22/19
17:42
Earnings
First Midwest reports Q3 adjusted EPS 52c, consensus 49c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 13

    Nov

GVA

Granite Construction

$36.76

0.44 (1.21%)

17:33
10/22/19
10/22
17:33
10/22/19
17:33
Hot Stocks
Granite Construction awarded $15M airfield contract in North Carolina »

Granite announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

REZI

Resideo

$15.17

0.03 (0.20%)

, STZ

Constellation Brands

$196.67

2.055 (1.06%)

17:32
10/22/19
10/22
17:32
10/22/19
17:32
Hot Stocks
Resideo CFO Joseph Ragan to leave company to pursue other opportunities »

Resideo Technologies…

REZI

Resideo

$15.17

0.03 (0.20%)

STZ

Constellation Brands

$196.67

2.055 (1.06%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SNAP

Snap

$14.00

-0.58 (-3.98%)

17:31
10/22/19
10/22
17:31
10/22/19
17:31
Hot Stocks
Snap says average revenue per user was $2.12 in Q3, an increase of 33% y-o-y »

Says maps and gaming are…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 21

    Nov

KFS

Kingsway Financial

$2.23

-0.045 (-1.98%)

17:28
10/22/19
10/22
17:28
10/22/19
17:28
Hot Stocks
NYSE extends Kingsway Financial deadline to be current with all SEC filings »

Kingsway Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REZI

Resideo

$15.17

0.03 (0.20%)

17:28
10/22/19
10/22
17:28
10/22/19
17:28
Hot Stocks
Resideo begins comprehensive operational and financial review »

Resideo has begun a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REZI

Resideo

$15.17

0.03 (0.20%)

17:27
10/22/19
10/22
17:27
10/22/19
17:27
Earnings
Resideo cuts FY19 revenue growth view to 2%-4% from 2%-5%, consensus $5.02B »

The company's new…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

REZI

Resideo

$15.17

0.03 (0.20%)

17:26
10/22/19
10/22
17:26
10/22/19
17:26
Earnings
Resideo reports preliminary Q3 revenue $1.226B, consensus $1.25B »

Reports preliminary Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HNGR

Hanger

$20.50

0.39 (1.94%)

, RTEC

Rudolph Technologies

$27.36

-0.12 (-0.44%)

17:21
10/22/19
10/22
17:21
10/22/19
17:21
Hot Stocks
Hanger to replace Rudolph Technologies in S&P 600 at open on 10/28 »

Nanometrics (NANO) is…

HNGR

Hanger

$20.50

0.39 (1.94%)

RTEC

Rudolph Technologies

$27.36

-0.12 (-0.44%)

NANO

Nanometrics

$34.01

0.03 (0.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

  • 07

    Nov

  • 08

    Nov

  • 13

    Nov

PSB

PS Business Parks

$184.20

-1.53 (-0.82%)

17:11
10/22/19
10/22
17:11
10/22/19
17:11
Earnings
PS Business Parks reports Q3 FFO $1.71, two estimates $1.73 »

Reports Q3 rental income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 12

    Nov

EPSN

Epsilon Energy

$3.20

(0.00%)

17:06
10/22/19
10/22
17:06
10/22/19
17:06
Hot Stocks
Epsilon Energy CEO comments on recent well results »

Michael Raleigh, CEO,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CALX

Calix

$7.15

0.005 (0.07%)

17:06
10/22/19
10/22
17:06
10/22/19
17:06
Earnings
Calix sees Q4 non-GAAP EPS 6c-10c, consensus 11c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

NOW

ServiceNow

$228.26

-12.315 (-5.12%)

17:05
10/22/19
10/22
17:05
10/22/19
17:05
Hot Stocks
Breaking Hot Stocks news story on ServiceNow »

ServiceNow down 6.3% at…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

  • 09

    Dec

  • 12

    Dec

CALX

Calix

$7.15

0.005 (0.07%)

17:05
10/22/19
10/22
17:05
10/22/19
17:05
Earnings
Calix reports Q3 non-GAAP EPS 6c, consensus 4c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

GSS

Golden Star Resources

$2.99

0.05 (1.70%)

17:04
10/22/19
10/22
17:04
10/22/19
17:04
Hot Stocks
Golden Star Resources to move corporate office, CFO Andre van Niekerk to leave »

Golden Star Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

TER

Teradyne

$59.24

-0.83 (-1.38%)

17:03
10/22/19
10/22
17:03
10/22/19
17:03
Earnings
Teradyne reports Q3 adjusted EPS 77c, consensus 70c »

Reports Q3 revenue $582M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 31

    Oct

UCBI

United Community Banks

$29.30

0.12 (0.41%)

17:02
10/22/19
10/22
17:02
10/22/19
17:02
Earnings
United Community Banks reports Q3 adjusted EPS 63c, consensus 58c »

On an operating basis,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Oct

  • 13

    Nov

NEM

Newmont Goldcorp

$37.80

-0.17 (-0.45%)

17:01
10/22/19
10/22
17:01
10/22/19
17:01
Hot Stocks
Newmont Goldcorp starting production at Penasquito Mine in Mexico »

Newmont Goldcorp is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Nov

ATR

AptarGroup

$116.78

-1.22 (-1.03%)

17:01
10/22/19
10/22
17:01
10/22/19
17:01
Hot Stocks
AptarGroup says Activ-Blister packaging solution approved by FDA »

AptarGroup announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

  • 12

    Nov

BUSE

First Busey

$25.45

0.05 (0.20%)

17:01
10/22/19
10/22
17:01
10/22/19
17:01
Earnings
First Busey reports Q3 adjusted EPS 55c, consensus 52c »

For the third quarter of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.